Is Viatris (VTRS) A Wise Investment Choice?

Davis Funds, an investment management firm, published its “Davis Opportunity Fund” third quarter 2021 investor letter – a copy of which can be downloaded here. In the year-to-date period through July 31, Davis Opportunity Fund returned 23.32%, outperforming the S&P 1500 Index’s 18.07% return. You can take a look at the fund’s top 5 holdings to have an idea about their best picks for 2021.

Davis Opportunity Fund, in its Q3 2021 investor letter, mentioned Viatris Inc. (NASDAQ: VTRS) and discussed its stance on the firm. Viatris Inc. is a Canonsburg, Pennsylvania-based global pharmaceutical company with a $14.7 billion market capitalization. VTRS delivered a -34.90% return since the beginning of the year, while its 12-month returns are down by -30.68%. The stock closed at $12.20 per share on December 03, 2021.

Here is what Davis Opportunity Fund has to say about Viatris Inc.  in its Q3 2021 investor letter:

“Also within healthcare, we own Viatris, the newly conceived union of Mylan, a generics/specialty pharma company, and Pfizer’s Upjohn business, which includes a portfolio of 20 largely off-patent branded Pfizer drugs including Lipitor, Lyrica, Norvasc and Viagra. The combined business is the largest generics/off-patent drug manufacturer in the world and is highly diversified by geography, with 70% of revenue outside the U.S.”

Based on our calculations, Viatris Inc. (NASDAQ: VTRS) was not able to clinch a spot in our list of the 30 Most Popular Stocks Among Hedge Funds. VTRS was in 55 hedge fund portfolios at the end of the third quarter of 2021, compared to 53 funds in the previous quarter. Viatris Inc. (NASDAQ: VTRS) delivered a -18.07% return in the past 3 months.

Disclosure: None. This article is originally published at Insider Monkey.